n INTRODUCTION R heumatoid arthritis (RA) is a chronic, multisystemic, autoimmune disease with no well-established etiology, which manifests itself with synovial hyperplasia, articular cartilage and bone destruction. In RA synovium, pannus formation occurs as a result of permanent and abnormal synoviocytes and various inflammatory cell proliferations (1, 2) . The cause of this chronic inflammation is not yet clear; however, one of the basic, major hypothesis is inadequate apoptosis (3, 4) . Many various molecules and receptors have been defined in the regulation of cell apoptosis; however, Fas-Fas ligand death receptor pathway is significantly involved in the pathogenesis of RA (5) . Fas(CD95) is a molecule that is expressed on the cell surface and initiates the signaling of death after binding its ligand (FasL). While Fas is expressed in many cells, FasL is expressed in exclusive regions such as the active T cells, the natural killer cells, the tumor cells and the eye. The Fas-FasL interaction accounts for the T-lymphocyte activation-mediated cell death, the natural killer cell and the T-lymphocyte cytotoxicity. In addition, they play an important role in lymphocyte homeostasis (6, 7) ; in vitro studies demonstrated a high level of Fas/FasL expression and secondary Fas-mediated susceptibility to apoptosis in synoviocytes, synovial T cells and macrophages (8) . Increased intra-synovial and/or serum sFas prevents the apoptosis of synoviocytes. Cytokines of stromal cell origin (e.g., TGF-b, TNF-alpha, IL-1, FGF) protect the RA synoviocytes against Fas-mediated apoptosis (9, 10) . RA T-lymphocytes are protected against apoptosis as a result of close connection with the fibroblast-like synoviocytes. In addition, RA synovial macrophages and fibroblasts pro-
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Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis vide the up-regulation of the FLIP and the sentrin (11) (12) (13) . At the same time, RA inhibits the nitric oxide (NO), caspase-3 and stromelysin-1 (14, 15) . Different intra-and extracellular pathways lead to impairment of Fas-mediated apoptosis in the RA joint. Fas and FasL play a significant role in the pathogenesis of various autoimmune diseases such as RA and SLE (16) . The impaired mechanisms of apoptosis and the increased Fas gene expression may result in a number of genetic disorders. An association was demonstrated between the Fas gene promoter polymorphism and the pathogenesis of diseases such as SLE and multiple sclerosis (17) . In the Fas gene promoter region, 2 single nucleotide polymorphisms were commonly demonstrated, namely -1377 G-A and -670 A-G. The biological impact of these polymorphisms is not well-established; while Fas-1377 polymorphism probably binds the transcription factor SP-1 sequences, Fas-670 is associated with the nuclear transcription factor GAS. Based on our hypothesis, the genetic variations occurring in the Fas/FasL promoter region may be significantly involved in the pathogenesis of RA by affecting apoptosis. The current study was designed to investigate the Fas/FasL promoter gene polymorphism, and demonstrate the association with disease activity, clinical and laboratory findings.
n MaTeRIals aND MeThODs
One hundred and one patients with RA under follow-up at a single center and 105 age and sex matched healthy control individuals were enrolled in the study. After obtaining a consent from all RA patients and the healthy subjects, peripheral blood samples were drawn into Na-EDTA containing tubes and stored at -80°C. The study was approved by the Regional Committee of Ethics.
Patients
One hundred and one (86 females) patients diagnosed with RA according to ACR classification criteria were enrolled in the study.
The mean patient age was 55.8 years, the mean disease duration was 8.3 years. The demographic and clinical features of RA patients are presented in Table I .
Genomic DNA preparation
Genomic DNA was extracted from ED-TA-anticoagulated whole blood samples using a commercially available genomic DNA purification kit (Nucleospin Blood L, Macherey-Nagel, Germany) following manufacturer's instructions. DNA concentration used by the PicoGreen dsDNA quantitation kit (Molecular Probes Inc., Eugene, OR, USA) using manufacturer's instructions which were diluted as 100 ng/µL.
PCR-restriction fragment length polymorphism (PCR-RFLP) genotyping for the Fas gene 670A/G polymorphism
The Fas-670A/G polymorphism was described previously with some minor modifications. Briefly, amplification was carried out on a GeneAmp PCR System 9700 (PE Applied Biosystems, Foster City, CA, USA) in a 25 µL reaction mixture in 0.2 mL thin-wall PCR strip tubes (Axygen Scientific, Inc., Union City, CA, USA) containing 1 µL genomic DNA solution, GeneAmp Gold Buffer (15 mmol/l TrisHCl, pH 8.0, 50 mmol/l KCl; PE Applied 
Digest conditions
Amplified 114 bp PCR product (7 µL) was digested in a 20-µcL final reaction volume using 2 µcL of Reaction Buffer 2 and 5 units of DraIII restriction enzyme (New England Biolabs, Beverly, MA, USA), at 37 C 3h. After digestion allele T yielded two fragments of 98 and 16 bp, whereas allele C wasn't digested and yielded 114 bp. Digested electrophoresis on gels containing a mixture of 1.5% Agarose (Sigma, St. Louis, MO, USA) and 1.5% NuSieve GTG (BMA, Rockland, ME, USA) was run for 1.5 h at 70 V and visualized after ethidium bromide staining in the BioDoc-It System Biolmaging systems (UVP).
Statistical analysis
The Hardy-Wainberg principle was used to test whether the patient and the control groups were balanced. Then, using the c 2 -test, the patients and the subjects genotype distribution and allele frequency were evaluated. The association of the genotype and allele frequency with the disease parameters was assessed by c 2 -test. The statistical analysis was performed using SPSS and P<0.05 was considered statistically significant.
n ResUlTs
Fas-670 G/A polymorphism
Fas/670 genotype distribution and the allele frequency were detected to be similar between the RA patient group and the healthy subject group (Tab. II). GA genotype and A allele were more frequent in both groups. Whilst no association among
Original article
Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis Fas gene polymorphism, the disease severity and certain clinical findings was determined, there was a statistically significant difference with anemia and anti-CCP antibodies (P<0.01, P<0.03, respectively) (Tab. III).
FasL-843 C/T polymorphism
FasL/844 genotype distribution and the allele frequency did not show a statistically significant difference between the RA patients and the healthy subject group (Tab. IV). CT genotype was more frequent in both groups (39.6% and 41.6%). There was no statistically significant difference in FasL gene polymorphism and the disease severity and the clinical parameters (Tab. V). 
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